REGIONAL REPORTS
EUROPE
This is a special supplement on HPV disease and prevention in the region authored by scientists and experts in the field.
Included countries are: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia,Hungary, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Montenegro, Poland, Republic of Moldova, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Tajikistan, the Former Yugoslav Republic of Macedonia, Turkmenistan, Ukraine, and Uzbekistan.
The supplement is presented as individual peer-reviewed articles on HPV as a major public health problem, including: HPV natural history and biology, HPV therapies, current screening strategies for cervical cancer including new technologies and prospects, prophylactic HPV vaccines and their introduction, economic analyses and gaps in knowledge.Prevention of cervical cancer in Central and Eastern Europe and Central Asia: a challenge for the future
Kesic V Vaccine. 2013;31 Suppl 7:vii-vix.
The path to eliminate cervical cancer in the world and the challenges of professional education
Bosch FX Vaccine. 2013;31 Suppl 7:xi-xii.
Comprehensive control of human papillomavirus infections and related diseases
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S Vaccine. 2013;31 Suppl 7:H1-H31.
Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia
Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M Vaccine. 2013;31 Suppl 7:H32-H45.
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia
Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjanen S, Poljak M Vaccine. 2013;31 Suppl 7:H46-H58.
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe
Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya SI, Arbyn M, Syrjanen S Vaccine. 2013;31 Suppl 7:H59-H70.
Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia
Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ Vaccine. 2013;31 Suppl 7:H71-H79.
Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia
Poljak M, Rogovskaya SI, Kesic V, Bray F, Berkhof J, Seme K, Brotons M, Castellsague X, Syrjanen S, Arbyn M, Bosch FX Vaccine. 2013;31 Suppl 7:H80-H82.
Specific information on European countries can be found in the scientific general reviews.
AMERICA
This is a special supplement on HPV disease and prevention in Latin America and Caribbean authored by scientists and experts in the field.
The supplement is presented as individual peer-reviewed articles on HPV as a major public health problem, including: HPV natural history and biology, HPV therapies, current screening strategies for cervical cancer including new technologies and prospects, prophylactic HPV vaccines and their introduction, economic analyses and gaps in knowledge.The war against cervical cancer in Latin America and the Caribbean. Triumph of the scientists. Challenge for the community
Correa Vaccine. 2008;26 Suppl 11:iii-iv.
A scientific response to prevent cervical cancer in the world
Bosch FX Vaccine. 2008;26 Suppl 11:v-vi.
Burden and trends of type-specific human papillomavirus infections and related diseases in the latin america and Caribbean region
Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Pineros Vaccine. 2008;26 Suppl 11:L1-L15.
Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean
Almonte M, Albero G, Molano M, Carcamo C, Garcia PJ, Perez Vaccine. 2008;26 Suppl 11:L16-L36.
Cervical cancer screening programs in Latin America and the Caribbean
Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jeronimo J, Lazcano-Ponce Vaccine. 2008;26 Suppl 11:L37-L48.
New approaches to cervical cancer screening in Latin America and the Caribbean
Herrero R, Ferreccio C, Salmeron J, Almonte M, Sanchez GI, Lazcano-Ponce E, Jeronimo Vaccine. 2008;26 Suppl 11:L49-L58.
Mathematical models of cervical cancer prevention in Latin America and the Caribbean
Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim S Vaccine. 2008;26 Suppl 11:L59-L72.
Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean
Winkler JL, Wittet S, Bartolini RM, Creed-Kanashiro HM, Lazcano-Ponce E, Lewis-Bell K, Lewis MJ, Penny M Vaccine. 2008;26 Suppl 11:L73-L79.
Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean
Andrus JK, Lewis MJ, Goldie SJ, Garcia PJ, Winkler JL, Ruiz-Matus C, de Quadros C Vaccine. 2008;26 Suppl 11:L80-L87.
Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean
Franco EL, Tsu V, Herrero R, Lazcano-Ponce E, Hildesheim A, Munoz N, Murillo R, Sanchez GI, Andrus J Vaccine. 2008;26 Suppl 11:L88-L95.
Recommendations for cervical cancer prevention in Latin America and the Caribbean
Munoz N, Franco EL, Herrero R, Andrus JK, de QC, Goldie SJ, Bosch FX Vaccine. 2008;26 Suppl 11:L96-L107.
Specific information on Northern American countries can be found in the scientific general reviews.
AFRICA
This is a special supplement on HPV disease and prevention in Sub-Saharan Africa authored by scientists and experts in the field.
Included countries are: Angola; Benin; Botswana; Burkina Faso; Burundi; Cameroon; Cape Verde; Central African Republic; Chad; Comoros; Congo; Côte d’Ivoire; Democratic Republic of Congo; Djibouti; Equatorial Guinea; Eritrea; Ethiopia; Gabon; Gambia; Ghana; Guinea; Guinea Bissau; Kenya; Lesotho; Liberia; Madagascar; Malawi; Mali; Mauritania; Mauritius; Mayotte; Mozambique; Namibia; Niger; Nigeria; Réunion; Rwanda; Saint Helena; Senegal; Seychelles; Sierra Leone; Somalia; South Africa; South Sudan; Sudan; Swaziland; Säo Tomé and Principe; Togo; Uganda; United Republic of Tanzania; Zambia; Zimbabwe.
The supplement is presented as individual peer-reviewed articles on HPV as a major public health problem, including: HPV natural history and biology, HPV therapies, current screening strategies for cervical cancer including new technologies and prospects, prophylactic HPV vaccines and their introduction, economic analyses and gaps in knowledge.Human papillomavirus infection and related cancers in sub-Saharan Africa: burden and tools for prevention
Awolude OA, Morhason-Bello IO, Denny LA, Adewole I Vaccine. 2013; 31 Suppl 5:vii-vix.
The path to eliminate cervical cancer in the world and the challenges of professional education
Bosch FX Vaccine. 2013; 31 Suppl 5:xi-xii.
Comprehensive control of human papillomavirus infections and related diseases
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S Vaccine. 2013; 31 Suppl 5:F1-F31.
The burden of human papillomavirus infections and related diseases in sub-saharan Africa
De VH, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham G Vaccine. 2013; 31 Suppl 5:F32-F46.
Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa
Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny L Vaccine. 2013; 31 Suppl 5:F47-F52.
Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa
Adefuye PO, Broutet NJ, de SS, Denny L Vaccine. 2013; 31 Suppl 5:F53-F59.
Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa
Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba Vaccine. 2013; 31 Suppl 5:F60-F72.
Recommendations for cervical cancer prevention in sub-saharan Africa
Denny LA, Sankaranarayanan R, De VH, Kim JJ, Adefuye PO, Alemany L, Adewole IF, Awolude OA, Parham G, de SS, Bosch FX Vaccine. 2013; 31 Suppl 5:F73-F74.
This is a special supplement on HPV disease and prevention in the Extended Middle East and North Africa region authored by scientists and experts in the field.
Included countries are: Algeria; Egypt; Libya; Morocco (including the Western Sahara); and Tunisia.
The supplement is presented as individual peer-reviewed articles on HPV as a major public health problem, including: HPV natural history and biology, HPV therapies, current screening strategies for cervical cancer including new technologies and prospects, prophylactic HPV vaccines and their introduction, economic analyses and gaps in knowledge.Extended Middle East and North Africa: cervical cancer and human papillomavirus: can we make the case for prevention in this 'relatively' low prevalence region?
Seoud M Vaccine. 2013;31 Suppl 6:vii-viii.
The path to eliminate cervical cancer in the world and the challenges of professional education
Bosch FX Vaccine. 2013;31 Suppl 6:ix-ix.
Comprehensive control of human papillomavirus infections and related diseases
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S Vaccine. 2013;31 Suppl 6:G1-G31.
Burden of human papillomavirus infections and related diseases in the extended Middle East and North Africa region
Vaccarella S, Bruni L, Seoud M Vaccine. 2013;31 Suppl 6:G32-G44.
Sexuality and sexual health: constructs and expressions in the extended Middle East and North Africa
El-Kak F Vaccine. 2013;31 Suppl 6:G45-G50.
Overview of cervical cancer screening practices in the extended Middle East and North Africa countries
Sancho-Garnier H, Khazraji YC, Cherif MH, Mahnane A, Hsairi M, El SA, Osgul N, Tuncer M, Jumaan AO, Seoud M Vaccine. 2013;31 Suppl 6:G51-G57.
Prospects and challenges in the introduction of human papillomavirus vaccines in the extended Middle East and North Africa region
Jumaan AO, Ghanem S, Taher J, Braikat M, Al AS, Dbaibo GS Vaccine. 2013;31 Suppl 6:G58-G64.
Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA)
Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M Vaccine. 2013;31 Suppl 6:G65-G77.
Extended Middle East and North Africa: summary recommendations for the prevention of human papillomavirus infections and related cancers including cervical cancer
Seoud M, Vaccarella S, El-Kak F, Sancho-Garnier H, Jumaan AO, Kim JJ, Garland SM, Stern PL, LaMontagne DS, Albero G, Bosch FX Vaccine. 2013;31 Suppl 6:G78-G79.
ASIA-PACIFIC
This is a special supplement on HPV disease and prevention in Extended Middle East and North Africa region (EMENA) authored by scientists and experts in the field.
Included countries are: Afghanistan; Bahrain; Iran; Iraq; Jordan; Kuwait; Lebanon; Oman; Pakistan; Qatar; Saudi Arabia; Syria; Turkey; United Arab Emirates; West Bank and Gaza; and Yemen.
The supplement is presented as individual peer-reviewed articles on HPV as a major public health problem, including: HPV natural history and biology, HPV therapies, current screening strategies for cervical cancer including new technologies and prospects, prophylactic HPV vaccines and their introduction, economic analyses and gaps in knowledge.Extended Middle East and North Africa: cervical cancer and human papillomavirus: can we make the case for prevention in this 'relatively' low prevalence region?
Seoud M Vaccine. 2013;31 Suppl 6:vii-viii.
The path to eliminate cervical cancer in the world and the challenges of professional education
Bosch FX Vaccine. 2013;31 Suppl 6:ix-ix.
Comprehensive control of human papillomavirus infections and related diseases
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S Vaccine. 2013;31 Suppl 6:G1-G31.
Burden of human papillomavirus infections and related diseases in the extended Middle East and North Africa region
Vaccarella S, Bruni L, Seoud M Vaccine. 2013;31 Suppl 6:G32-G44.
Sexuality and sexual health: constructs and expressions in the extended Middle East and North Africa
El-Kak F Vaccine. 2013;31 Suppl 6:G45-G50.
Overview of cervical cancer screening practices in the extended Middle East and North Africa countries
Sancho-Garnier H, Khazraji YC, Cherif MH, Mahnane A, Hsairi M, El SA, Osgul N, Tuncer M, Jumaan AO, Seoud M Vaccine. 2013;31 Suppl 6:G51-G57.
Prospects and challenges in the introduction of human papillomavirus vaccines in the extended Middle East and North Africa region
Jumaan AO, Ghanem S, Taher J, Braikat M, Al AS, Dbaibo GS Vaccine. 2013;31 Suppl 6:G58-G64.
Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA)
Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M Vaccine. 2013;31 Suppl 6:G65-G77.
Extended Middle East and North Africa: summary recommendations for the prevention of human papillomavirus infections and related cancers including cervical cancer
Seoud M, Vaccarella S, El-Kak F, Sancho-Garnier H, Jumaan AO, Kim JJ, Garland SM, Stern PL, LaMontagne DS, Albero G, Bosch FX Vaccine. 2013;31 Suppl 6:G78-G79.
This is a special supplement on HPV disease and prevention in the Asia-Pacific region authored by scientists and experts in the field.
Included countries are Bangladesh; Bhutan; Brunei; Cambodia; China; Hong Kong SAR; India; Indonesia; Japan; Republic of Korea; Laos; Malaysia; Mongolia; Myanmar; Nepal; Pakistan; Philippines; Singapore; Southern Asia; Sri Lanka; Taiwan; Thailand; Timor-Leste; Viet Nam; and Australasia (Australia and New Zealand) and Oceania.
The supplement is presented as individual peer-reviewed articles on HPV as a major public health problem, including: HPV natural history and biology, HPV therapies, current screening strategies for cervical cancer including new technologies and prospects, prophylactic HPV vaccines and their introduction, economic analyses and gaps in knowledge.Asia Pacific: cervical cancer screening and human papillomavirus vaccination policy and delivery
Shah K Vaccine. 2008;26 Suppl 12:iii-iiv.
A scientific response to prevent cervical cancer in the world
Bosch FX Vaccine. 2008;26 Suppl 12:v-vi.
Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region
Parkin DM, Louie KS, Clifford Vaccine. 2008;26 Suppl 12:M1-M16.
Mathematical models of cervical cancer prevention in the Asia Pacific region
Goldie SJ, Diaz M, Kim SY, Levin CE, Van MH, Kim J Vaccine. 2008;26 Suppl 12:M17-M29.
Human papillomavirus infection and cervical cancer prevention in Japan and Korea
Konno R, Shin HR, Kim YT, Song YS, Sasagawa T, Inoue M, Park J Vaccine. 2008;26 Suppl 12:M30-M42.
Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal
Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO, Ashrafunnessa KS, Ariyaratne Y, Shah A, Nene B Vaccine. 2008;26 Suppl 12:M43-M52.
Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia
Shi JF, Qiao YL, Smith JS, Dondog B, Bao YP, Dai M, Clifford GM, Franceschi Vaccine. 2008;26 Suppl 12:M53-M59.
Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan
Tay SK, Ngan HY, Chu TY, Cheung AN, Tay E Vaccine. 2008;26 Suppl 12:M60-M70.
Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam
Domingo EJ, Noviani R, Noor MR, Ngelangel CA, Limpaphayom KK, Thuan TV, Louie KS, Quinn M Vaccine. 2008;26 Suppl 12:M71-M79.
Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention
Garland SM, Brotherton JM, Skinner SR, Pitts M, Saville M, Mola G, Jones R Vaccine. 2008;26 Suppl 12:M80-M88.
Recommendations for cervical cancer prevention in Asia Pacific
Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX Vaccine. 2008;26 Suppl 12:M89-M98.
This is a special supplement on HPV disease and prevention in Israel authored by scientists and experts in the field.
The supplement is presented as individual peer-reviewed articles on HPV as a major public health problem, including: HPV natural history and biology, HPV therapies, current screening strategies for cervical cancer including new technologies and prospects, prophylactic HPV vaccines and their introduction, economic analyses and gaps in knowledge.Human papillomavirus-associated diseases in Israel--the controversy continues. Foreword
Bornstein J, Shavit O Vaccine. 2013;31 Suppl 8:vii-vix.
The path to eliminate cervical cancer in the world and the challenges of professional education. Preface
Bosch FX Vaccine. 2013;31 Suppl 8:xi-xii.
Comprehensive control of human papillomavirus infections and related diseases
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S Vaccine. 2013;31 Suppl 8:I1-31.
Burden of human papillomavirus infection and related diseases in Israel
Shavit O, Roura E, Barchana M, Diaz M, Bornstein J Vaccine. 2013;31 Suppl 8:I32-I41.
Cervical cancer screening, human papillomavirus vaccination practices and current infrastructure in Israel
Schejter E, Bornstein J, Siegler E Vaccine. 2013;31 Suppl 8:I42-I45.
Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel
Ginsberg GM Vaccine. 2013;31 Suppl 8:I46-I52.
Barriers to human papillomavirus vaccine acceptability in Israel
Fisher WA, Laniado H, Shoval H, Hakim M, Bornstein J Vaccine. 2013;31 Suppl 8:I53-I57.
Screening for cervical cancer and human papillomavirus vaccination in Israel: recommendations
Bornstein J, Fisher WA, Ginsberg GM, Shavit O, Schejter E, Diaz M, Bosch FX Vaccine. 2013;31 Suppl 8:I58-I60.
Specific information on Australia and New Zealand can also be found in the scientific general reviews.
GAVI COUNTRIES
This is a special report of the HPV Information Centre on the statistics of HPV and cancer prevention for the GAVI countries. This summary report provides key information for the 2012 GAVI-eligible countries on the burden of cervical cancer, other anogenital cancers and head and neck cancers, HPV- related statistics, factors contributing to cervical cancer, cervical cancer screening practices, HPV vaccine introduction, and other relevant indicators.